EASD 2025 15 - 19 September 2025

Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: Data from REDEFINE 1

Authors :

W. Timothy Garvey¹; Lei Liu²; John Rømer²; Kirsi H. Pietiläinen³; Ketil Biering Tvermosegaard²; David C.W. Lau⁴

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Download poster (.pdf)

Keywords

Obesity

Congress short oral presentation

GLP-1 RA

Cagrilintide

PHASE 3 (RCT)